Incyte changes manufacturing process, adds second site to solve Opzelura texture issue

Josh Sullivan

From the start of Incyte’s Q1 earnings call, the manufacturing issues surrounding Opzelura were addressed by Hervé Hoppenot, the company’s CEO. And though issues have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Incyte changes manufacturing process, adds second site to solve Opzelura texture issue

Josh Sullivan

Sign up to read this article for free.

Lilly drops body mass ranges from FDA label for weight loss drug

Coherus makes final, $483M pivot away from biosimilars

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

In­cyte changes man­u­fac­tur­ing process, adds sec­ond site to solve Opzelu­ra tex­ture is­sue

Josh Sullivan

Sign up to read this article for free.

more like this

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Incyte changes manufacturing process, adds second site to solve Opzelura texture issue

Lilly drops body mass ranges from FDA label for weight loss drug

Coherus makes final, $483M pivot away from biosimilars

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech